TeresaCGentileMD

Oncology • Syracuse, NY

Associate Professor, Medicine, SUNY-Upstate Medical University

Join to view full profile

Dr. Gentile is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Gentile's full profile

Already have an account?

Office
750 E Adams St
Regional Oncology Center
Syracuse, NY 13210
Phone+1 315-464-8200

Fax+1 315-464-8206

Education & Training

SUNY Upstate Medical UniversityFellowship, Hematology and Medical Oncology, 1993 - 1996
SUNY Upstate Medical UniversityResidency, Internal Medicine, 1989 - 1993
SUNY Upstate Medical UniversityClass of 1989

Certifications & Licensure

NY State Medical License 1991 - 2025
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702) Start of enrollment: 2010 May 01
Completed
Phase 3
Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma Start of enrollment: 2012 Dec 01
Active, not recruiting
Phase 2
Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma Start of enrollment: 2013 Aug 27
Active, not recruiting
Phase 2
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2013 Dec 09
Active, not recruiting
Phase 3
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2014 Feb 20
Active, not recruiting
Phase 3
R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma Start of enrollment: 2016 May 20
Active, not recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

2 citations
Utilization and outcome disparities in allogeneic hematopoietic stem cell transplant in the United States.
Prashanth Ashok Kumar, Krishna Ghimire, Elio Haroun, Joseph Kassab, Ludovic Saba
European Journal of Haematology. 2024-03-01
Descriptive Analysis and Factors Influencing Survival in Patients With Primary Cutaneous Gamma-Delta T Cell Lymphoma. A Retrospective National Cancer Database Study.
Prashanth Ashok Kumar, Abirami Sivapiragasam, Dongliang Wang, Danning Huang, Teresa Gentile
Clinical Lymphoma, Myeloma & Leukemia. 2023-12-01
1 citations
Systemic Cancer Therapy Does Not Significantly Impact Early Vaccine-Elicited SARS-CoV-2 Immunity in Patients with Solid Tumors.
Adam T Waickman, Joseph Lu, Corey Chase, Hengsheng Fang, Erinn McDowell
Vaccines. 2022-05-09

Press Mentions

Resident ReportJune 30th, 2018